Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Good

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Medicinal Chemistry Research : an International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents|June 26, 2023
Discovery of pyrrolo[2,1-<i>f</i>][1,2,4]triazine-based inhibitors of adaptor protein 2-associated kinase 1 for the treatment of painCarolyn D Dzierba, Bireshwar Dasgupta, George Karageorge, et al.
Cancer Research|October 28, 2025
CFT1946 is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader that Overcomes BRAF Inhibitor ResistanceBridget T Kreger, Yanke Liang, Nicole M Reilly, et al.
RSC Medicinal Chemistry|August 18, 2025
Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degraderDouglas L Orsi, Kiel E Lazarski, Reina Improgo, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Medicinal Chemistry Research : an International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents|June 26, 2023
Discovery of pyrrolo[2,1-<i>f</i>][1,2,4]triazine-based inhibitors of adaptor protein 2-associated kinase 1 for the treatment of painCarolyn D Dzierba, Bireshwar Dasgupta, George Karageorge, et al.
Cancer Research|October 28, 2025
CFT1946 is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader that Overcomes BRAF Inhibitor ResistanceBridget T Kreger, Yanke Liang, Nicole M Reilly, et al.
RSC Medicinal Chemistry|August 18, 2025
Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degraderDouglas L Orsi, Kiel E Lazarski, Reina Improgo, et al.
Pageof 2